PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jvirolPermissionsJournals.ASM.orgJournalJV ArticleJournal InfoAuthorsReviewers
 
J Virol. 2012 March; 86(5): 2878–2881.
PMCID: PMC3302278

Immune Correlates of Herpes Zoster in HIV-Infected Children and Youth

Abstract

To identify immunologic factors that modulate the risk of herpes zoster (HZ), we compared varicella-zoster virus (VZV)-specific and nonspecific T-cell subpopulations of 47 HIV-infected children before they developed HZ with those of 141 VZV-positive HZ-negative matched controls. Compared with controls, HZ cases had lower VZV-specific CD8+ CD107a+ cell percentages independently of CD4+ percentages or HIV loads, suggesting that VZV-specific cytotoxic T cells are protective against HZ. In contrast, high nonspecific regulatory and activated T cells were associated with an increased risk of HZ.

TEXT

Herpes zoster (HZ) was a very common complication of HIV disease before the advent of highly active antiretroviral therapy (HAART) (7, 40) and remains relatively frequent in spite of the widespread application of HAART (39, 23). This is consistent with previous observations that HIV-infected individuals on HAART may not fully recover varicella-zoster virus (VZV)-specific cell-mediated immune (CMI) responses (14, 45).

Patients at high risk of developing HZ typically have lower VZV-specific functional responses in CD4+ and CD8+ T-cell subsets (31) than low-risk individuals. However, it is not known if one or both T-cell subsets are directly involved in preventing VZV reactivation and/or spread (2).

An HZ vaccine is efficacious in individuals who are ≥50 years old (30, 34). HIV-infected children on HAART are candidates for this vaccine due to their persistently high incidence of HZ. However, HIV-infected children have deficient responses to vaccines in spite of HAART (3, 24, 25, 43). Since immunogenicity will be an important endpoint for a study of the HZ vaccine in this population, establishing immune correlates of protection against HZ would represent an important outcome variable.

Mechanisms responsible for poor functional immune reconstitution in HIV-infected individuals on HAART are not well understood. HIV-infected individuals have high proportions of regulatory T cells (Treg) (1, 5), which may contribute to failure to fully reconstitute immunity to VZV and other pathogens (8). Both human and mouse CD4+ Treg characteristically express FoxP3 (4, 1113, 20). Other markers that identify Treg are expression of CD25, lack of CD127, and synthesis of transforming growth factor β (TGF-β) or interleukin 10 (IL-10) (15, 26, 27, 29, 35, 38). Less is known about CD8+ Treg, which also contribute to deactivation of the immune response and tolerance (10, 19, 22, 41, 42).

We investigated associations between the incidence of HZ in HIV-infected children and the presence of VZV-specific effector T cells (Teff) and nonspecific Treg in their peripheral blood mononuclear cells (PBMC).

This was a case-control study using cryopreserved PBMC from subjects enrolled in the IMPAACT/PACTG 219/219c long-term follow-up cohort. HZ cases from 1994 to 2004 were matched 1:3 to controls (previous varicella but without HZ) by age, nadir CD4 percentages, utilization of HAART, and time since the last active VZV infection (≤1 year or >1 year) (44).

For Treg, freshly thawed PBMC were surface stained with anti-CD4, -CD8, -CD25 (Beckman Coulter), and -TGF-β (IQP Products) and intracellularly with anti-TGF-β, -FoxP3 (eBioscience), -PD-1, and -IL-10 (BD Biosciences). For Teff, PBMC were stimulated for 5 days with the cell-associated VZV Oka vaccine strain (9.6 × 104 PFU/ml) or medium. The virus was grown in primary human lung fibroblasts. On day four, brefeldin A (Sigma) and anti-CD107a (BD Biosciences) were added (6). On day five, PBMC were surface stained for CD4, CD8, CD25, and TGF-β and intracellularly for IL-2, tumor necrosis factor alpha (TNF-α), (eBioscience), MIP-1β, and gamma interferon (IFN-γ) (BD Biosciences). Flow cytometric analyses were done with the Guava EasyCyte Plus system (Millipore) and the FlowJo software program (Treestar). VZV-specific Teff and Treg were expressed as percentages of the parent CD4+ or CD8+ lymphocytes.

Fisher's exact test was used for categorical variables and a generalized estimating equation (GEE) was used for continuous variables while accounting for matching. For continuous variables with small sample sizes, the Wilcoxon rank-sum test was used. Spearman's rank order correlation analysis was performed to examine the strength and statistical significance of associations. Multivariable analyses used standard logistic regression to examine the predictive value of Treg or Teff while controlling for CD4+ cell percentages and/or plasma HIV RNA copies/ml. Since this was an exploratory study, no adjustments were made for multiple comparisons, which may have created an overly conservative criterion resulting in our missing suggestive findings. The P values of the differences may be overestimates.

Forty-seven subjects met inclusion criteria for HZ cases; 141 matched controls were identified (Table 1). HZ cases had significantly lower CD4+ cell percentages and higher HIV loads but no other differences.

Table 1
Demographic and HIV disease characteristics when PBMC were obtained

Nine of 47 cases and 33 of 141 controls had sufficient PBMC to perform the stimulation assays (Table 2). Compared with controls, cases had higher or similar but not lower expression of Th1 markers by CD4+ T cells. Specifically, CD4+ MIP-1β+ and CD4+ IL-2+ cell percentages were higher under VZV-stimulated and unstimulated conditions. No significant differences were observed in CD4+ TNF-α+ or CD4+ IFN-γ+ percentages or in any double-positive populations under VZV-stimulated or unstimulated conditions. In contrast, VZV-stimulated CD8+ CD107a+ cell percentages were significantly lower for cases than for controls (P = 0.02). No significant differences were observed in unstimulated CD8+ CD107a+ cell percentages(P = 0.42) or other CD8+ subpopulations.

Table 2
VZV-specific and nonspecific Teff in HIV-infected children and adolescents with HZ and their matched controlsa

In a multivariable analysis that included VZV-specific CD8+ CD107+ cell percentages, CD4+ percentages, and plasma HIV RNA copies/ml, only a low CD8+ CD107+ cell percentage remained significantly associated with HZ, indicating its strong predictive value for protection against HZ in HIV-infected children and adolescents.

Treg were measured in PBMC of 33 cases and 100 controls (Table 3). Compared with controls, HZ cases had significantly higher CD4+ TGF-β+, CD4+ IL-10+, and CD4+ PD1+ cell percentages. The total CD4+ FoxP3+ percentages and the CD4+ FoxP3+ CD25+ Treg percentages tended to be higher in HZ cases. No significant differences were observed for CD8+ Treg.

Table 3
Nonspecific Treg in HIV-infected children and adolescents with HZ and their matched controls

In a multivariable analysis controlling for CD4+ cell percentages, higher CD4+ TGF-β+ and CD4+ PD1+ percentages remained significantly associated with the occurrence of HZ (P = 0.03), but CD4+ IL-10+ percentages did not. When plasma HIV RNA levels were controlled for, however, neither the Treg subpopulations nor the CD4+ cell percentages maintained significance.

To understand the factors that affect the frequency of Treg in HIV-infected children and adolescents, we performed correlation analyses of the CD4+ Treg subpopulations with CD4+ percentages and plasma HIV RNA concentrations (Table 4). Higher CD4+ FoxP3+ and CD4+ TGF-β+ percentages were weakly associated with lower CD4+ percentages and higher plasma HIV RNA levels. In contrast, higher CD4+ IL-10+ and CD4+ PD1+ percentages were associated with higher CD4+ percentages and lower plasma HIV RNA levels. CD4+ CD25+ FoxP3+ percentages were not significantly associated with CD4+ percentages or plasma HIV RNA levels.

Table 4
Correlations between Treg and HIV disease characteristicsa

Among the effector T cell populations, only the CD8+ CD107a+ percentages were significantly lower prior to HZ cases than for non-HZ controls, suggesting that these cytotoxic T lymphocytes (CTL) are important in protecting against HZ. It is likely that when VZV reactivates, CTL eliminate VZV-infected cells and thereby limit viral replication and prevent disease. Studies in healthy individuals demonstrated a robust VZV-specific CD8+ CTL response to VZV infections (17, 36), although the protective effect of CD8+ CD107a+ effectors against VZV disease or asymptomatic reactivation had not previously been established. The strength of our results is tempered by the limited number of samples tested. However, our finding has strong biologic plausibility, and the association between high levels of CTL and a low risk of HZ was independent of CD4+ percentages and HIV loads, which frequently dominate this type of correlation analysis. The HZ vaccine stimulates VZV-specific CD8+ cells in immunocompetent vaccinees (31), and it will be important to determine if it also boosts VZV-specific CTL in HIV-infected individuals.

High frequencies of VZV-specific CD4+ memory T cells have been associated with protection against HZ in elderly individuals and transplant recipients, groups that are at as high a risk of developing HZ as the HIV-infected individuals (16, 28, 46, 47). In our study, HZ cases had lower CD4+ percentages than non-HZ controls, which is in agreement with previous reports (40). However, using traditional Teff markers, we did not find significant associations between protection against HZ and the proportions of CD4+ Teff. This may have been an artifact of the small number of samples tested but may also indicate that VZV-specific CD4+ Teff are not fully functional in HIV-infected individuals or that they may be too few for an effective anti-VZV response.

It is noteworthy that IL-2 and MIP-1β expression was more common in CD4+ T cells of HZ cases, but this was not VZV specific, probably reflecting higher level of T cell activation in HZ cases. HZ cases had more HIV replication than matched controls, providing a potential explanation of the difference in T-cell activation. It is unclear if this higher level of nonspecific T-cell activation contributes to VZV reactivation and/or to the viral expansion necessary for the genesis of symptomatic disease.

We found that higher CD4+ IL-10+ percentages, CD4+ TGF-β+ percentages, and CD4+ PD1+ percentages were associated with an increased risk of HZ. These data are the first demonstration of an association between Treg frequencies and development of HZ. Higher frequencies of Treg may increase the risk of HZ by several mechanisms: (i) cytokines and other mediators secreted by Treg may stimulate VZV reactivation, and (ii) Treg inhibition of Teff could allow reactivated VZV to spread in the dorsal root ganglion, travel to the skin and/or invade the bloodstream (i.e., become clinically apparent), and/or promote VZV infection of skin.

The multivariable and correlation analyses of Treg, CD4+ percentages, and plasma HIV load showed that the relationship of all Treg subpopulations with development of HZ was associated with HIV replication, while the relationship of CD4+ TGF-β+ percentages and CD4+ PD1+ percentages with HZ was independent of CD4+ percentages. Moreover, higher CD4+ TGF-β+ percentages were found in subjects with lower CD4+ percentages and higher plasma HIV RNA. Taken together, this suggests that CD4+ TGF-β+ Treg increase in response to HIV replication and/or promote HIV replication and consequent CD4+ T-cell depletion while simultaneously promoting VZV reactivation and/or replication. This suggests that the CD4+ TGF-β+ Treg have nonspecific regulatory activity.

The dynamics of the CD4+ PD1+ cells is more complex, since higher CD4+ PD1+ percentages were observed in subjects with higher CD4+ percentages and lower HIV loads. PD1 expression is found in regulatory, activated, or exhausted T cells. The regulatory activity of CD4+ PD1+ cells was originally described for mice (33, 37), where it was proposed that unlike the surface expression by conventional CD4+ PD1+ cells, CD4+ PD1+ Treg maintained PD1 in the cytoplasm (32). We measured intracellular PD1. A recent publication proposed that human CD4+ PD1+ cells represent memory cells (9). Although our findings that CD4+ PD1+ percentages increase with higher CD4+ percentages and decrease with higher HIV replication differ from findings for other Treg studied here, this pattern is still consistent with the behavior described in some studies for Treg subpopulations of HIV-infected individuals (18, 21). Furthermore, it is unclear how higher frequencies of memory T cells would predispose to a higher incidence of HZ. Hence, it is most likely that the CD4+ PD1+ cells detected in excess in HZ cases represent Treg.

In conclusion, in addition to the protective role of VZV-specific CD8+ CTL against HZ, we demonstrated in HIV-infected children and adolescents that higher frequencies of Treg and higher T cell activation are associated with an increased risk of HZ. Further studies are needed to identify the mechanisms by which these T cell subpopulations contribute to the development of HZ and if they are also associated with a higher incidence of HZ in other high-risk individuals.

ACKNOWLEDGMENTS

We thank the IMPAACT/PACTG 219/219c participants and clinical site personnel and teams.

This research was supported by grant 5 MO1-RR00069, General Clinical Research Centers Program, National Center for Research Resources, NIH, grant N01-HD-3-3162, grants U01AI068632 and 1 U01 AI068616 from the National Institute of Allergy and Infectious Diseases, and N01-HD-3-3345 and contract N01-HD-33162 (to A.W.) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development.

The content is solely our responsibility and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, or the National Institutes of Health.

Footnotes

Published ahead of print 14 December 2011

REFERENCES

1. Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon DF. 2004. Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J. Virol. 78:2454–2459. [PMC free article] [PubMed]
2. Abendroth A, Kinchington PR, Slobedman B. 2010. Varicella zoster virus immune evasion strategies. Curr. Top. Microbiol. Immunol. 342:155–171. [PubMed]
3. Abzug MJ, et al. 2006. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr. Infect. Dis. J. 25:920–929. [PubMed]
4. Allan SE, et al. 2005. The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. J. Clin. Invest. 115:3276–3284. [PMC free article] [PubMed]
5. Andersson J, et al. 2005. The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients. J. Immunol. 174:3143–3147. [PubMed]
6. Betts MR, Koup RA. 2004. Detection of T-cell degranulation: CD107a and b. Methods Cell Biol. 75:497–512. [PubMed]
7. Buchbinder SP, et al. 1992. Herpes zoster and human immunodeficiency virus infection. J. Infect. Dis. 166:1153–1156. [PubMed]
8. Chougnet CA, Shearer GM. 2007. Regulatory T cells (Treg) and HIV/AIDS: summary of the September 7–8, 2006 workshop. AIDS Res. Hum. Retroviruses 23:945–952. [PubMed]
9. Duraiswamy J, et al. 2011. Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults. J. Immunol. 186:4200–4212. [PubMed]
10. Endharti AT, et al. 2005. Cutting edge: CD8+CD122+ regulatory T cells produce IL-10 to suppress IFN-gamma production and proliferation of CD8+ T cells. J. Immunol. 175:7093–7097. [PubMed]
11. Fantini MC, et al. 2004. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25− T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol. 172:5149–5153. [PubMed]
12. Fontenot JD, Rudensky AY. 2005. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat. Immunol. 6:331–337. [PubMed]
13. Gavin MA, et al. 2006. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc. Natl. Acad. Sci. U. S. A. 103:6659–6664. [PubMed]
14. Gershon AA, et al. 2009. A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella. Pediatr. Infect. Dis. J. 28:653–655. [PMC free article] [PubMed]
15. Hansen W, et al. 2006. G protein-coupled receptor 83 overexpression in naive CD4+CD25− T cells leads to the induction of Foxp3+ regulatory T cells in vivo. J. Immunol. 177:209–215. [PubMed]
16. Hata A, et al. 2002. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N. Engl. J. Med. 347:26–34. [PubMed]
17. Hayward A, Giller R, Levin M. 1989. Phenotype, cytotoxic, and helper functions of T cells from varicella zoster virus stimulated cultures of human lymphocytes. Viral Immunol. 2:175–184. [PubMed]
18. Hunt PW, et al. 2011. A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS One 6:e15924. [PMC free article] [PubMed]
19. Jesser RD, Li S, Weinberg A. 2006. Regulatory T cells generated during cytomegalovirus in vitro stimulation of mononuclear cells from HIV-infected individuals on HAART correlate with decreased lymphocyte proliferation. Virology 352:408–417. [PubMed]
20. Jonuleit H, Schmitt E. 2003. The regulatory T cell family: distinct subsets and their interrelations. J. Immunol. 171:6323–6327. [PubMed]
21. Kared H, et al. 2008. HIV-specific regulatory T cells are associated with higher CD4 cell counts in primary infection. AIDS 22:2451–2460. [PMC free article] [PubMed]
22. Koenen HJ, Fasse E, Joosten I. 2005. CD27/CFSE-based ex vivo selection of highly suppressive alloantigen-specific human regulatory T cells. J. Immunol. 174:7573–7583. [PubMed]
23. Levin MJ, Anderson JP, Seage GR, III, Williams PL. 2009. Short-term and long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected children. J. Acquir. Immune Defic. Syndr. 50:182–191. [PMC free article] [PubMed]
24. Levin MJ, et al. 2001. Immunization of HIV-infected children with varicella vaccine. J. Pediatr. 139:305–310. [PubMed]
25. Levin MJ, et al. 2006. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells. J. Infect. Dis. 194:247–255. [PubMed]
26. Levings MK, et al. 2005. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood 105:1162–1169. [PubMed]
27. Liu W, et al. 2006. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med. 203:1701–1711. [PMC free article] [PubMed]
28. Malavige GN, et al. 2008. Viral load, clinical disease severity and cellular immune responses in primary varicella zoster virus infection in Sri Lanka. PLoS One 3:e3789. [PMC free article] [PubMed]
29. Myers L, Croft M, Kwon BS, Mittler RS, Vella AT. 2005. Peptide-specific CD8 T regulatory cells use IFN-gamma to elaborate TGF-beta-based suppression. J. Immunol. 174:7625–7632. [PubMed]
30. Oxman MN, et al. 2005. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med. 352:2271–2284. [PubMed]
31. Patterson-Bartlett J, et al. 2007. Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine. Vaccine 25:7087–7093. [PubMed]
32. Raimondi G, Shufesky WJ, Tokita D, Morelli AE, Thomson AW. 2006. Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells. J. Immunol. 176:2808–2816. [PubMed]
33. Sandner SE, et al. 2005. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J. Immunol. 174:3408–3415. [PubMed]
34. Schmader K, et al. 2010. Efficacy, immunogenicity, safety, and tolerability of zoster vaccine (ZV) in subjects 50 to 59 years of age. Prog. Abstr. Infect. Dis. Soc. Am. 48th Annu. Meet., abstr 3363.
35. Seddiki N, et al. 2006. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med. 203:1693–1700. [PMC free article] [PubMed]
36. Sharp M, et al. 1992. Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine. J. Infect. Dis. 165:852–858. [PubMed]
37. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. 2007. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8:239–245. [PubMed]
38. Sugimoto N, et al. 2006. Foxp3-dependent and -independent molecules specific for CD25+CD4+ natural regulatory T cells revealed by DNA microarray analysis. Int. Immunol. 18:1197–1209. [PubMed]
39. Vanhems P, et al. 2005. The incidence of herpes zoster is less likely than other opportunistic infections to be reduced by highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 38:111–113. [PubMed]
40. Veenstra J, et al. 1995. Herpes zoster, immunological deterioration and disease progression in HIV-1 infection. AIDS 9:1153–1158. [PubMed]
41. Vlad G, Cortesini R, Suciu-Foca N. 2005. License to heal: bidirectional interaction of antigen-specific regulatory T cells and tolerogenic APC. J. Immunol. 174:5907–5914. [PubMed]
42. Walker MR, Carson BD, Nepom GT, Ziegler SF, Buckner JH. 2005. De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD25− cells. Proc. Natl. Acad. Sci. U. S. A. 102:4103–4108. [PubMed]
43. Weinberg A, et al. 2006. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. J. Infect. Dis. 193:302–311. [PubMed]
44. Weinberg A, et al. 2010. Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses. J. Infect. Dis. 201:1024–1030. [PMC free article] [PubMed]
45. Weinberg A, Wiznia AA, LaFleur BJ, Shah S, Levin MJ. 2004. Varicella-zoster virus-specific cell-mediated immunity in HIV-infected children receiving highly active antiretroviral therapy. J. Infect. Dis. 190:267–270. [PubMed]
46. Weinberg A, et al. 2009. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine J. Infect. Dis. 200:1068–1077. [PubMed]
47. Wilson A, Sharp M, Koropchak CM, Ting SF, Arvin AM. 1992. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J. Infect. Dis. 165:119–126. [PubMed]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)